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Abstract
Rationale and Objectives: To apply a decision analysis model for evaluation of coronary artery
disease (CAD) to define optimal utilization of cCTA and stress testing.

Materials and Methods: Our model assumes CAD is evaluated with a stress test and/or cCTA,
and that a patient with a positive evaluation undergoes cardiac catheterization. Based upon values
of sensitivity, specificity and radiation dose from the published literature and test costs from the
Medicare fee schedule, a decision tree model was constructed as a function of disease prevalence.

Results: False negative rate (FNR) is lowest when cCTA is used as an isolated test. False positive
rate (FPR) is minimized when cCTA is employed in combination with stress echocardiography.
Effective radiation is minimized by use of stress ECG or stress echocardiography alone, or prior
to cCTA. When the pretest probability of CAD is low, a strategy that employs stress
echocardiography followed by cCTA minimizes FPR and effective radiation exposure, with
relatively low imaging costs and with a FNR only slightly higher than a stress myocardial
scintigraphy strategy. As the pretest probability of CAD increases above 20%, the FNR of stress
echocardiography followed by cCTA increases by more than 5% relative to cCTA alone.

Conclusion: Effective radiation dose and imaging costs for the work-up of CAD may be
minimized by an appropriate combination of stress testing and cCTA. A strategy that employs
stress echocardiography followed by cCTA is appropriate for evaluation of the low risk CAD
patient with a pre-test probability less than 20%, while cCTA alone may be more appropriate in
the intermediate risk patient.
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Introduction

Although the age-adjusted death rate from heart disease has been declining
slowly over the past 50 years, heart disease remains the most common cause of
death in the United States, and was responsible for 26% of all deaths in 2006.1
Atherosclerotic disease of the coronary arteries remains the most important etiology
of heart disease. The evaluation of suspected coronary artery disease (CAD) should
always begin with an appropriate history, physical examination and ECG. In the
stable, symptomatic patient evaluation for CAD often progresses to non-invasive
stress testing. The stress test provides a physiological evaluation of cardiac function
and serves as a diagnostic study and prognostic marker for future coronary events.2
Coronary computed tomographic angiography (cCTA) provides a noninvasive alternative to cardiac catheterization for visualization of coronary anatomy,
and has demonstrated high sensitivity and specificity for the anatomic presence of
CAD.3,4 Although functional information about wall motion can be obtained during
cCTA, the primary utility of cCTA is for imaging of the coronary arteries to define
the presence of CAD. Stress testing provides additional information to predict the
functional relevance of coronary stenosis with respect to myocardial ischemia.5,6
When cCTA demonstrates coronary stenosis of uncertain hemodynamic
significance, a follow-up stress test may evaluate the functional significance of
CAD found by cCTA. Given the divergent emphasis of stress testing on functional
physiology and cCTA on coronary anatomy, these two modalities may provide
complementary information in the evaluation of CAD.7
Stress testing has served as the traditional test of choice to evaluate
symptoms that may be related to CAD. Three broad categories of stress testing
include stress ECG without imaging, stress echocardiography and the nuclear stress

test – myocardial perfusion scintigraphy (stress MPS). Although cCTA may be
more accurate than stress testing for evaluation of “hemodynamically significant”
coronary stenosis8 and appropriateness criteria have been evaluated for the
application of cCTA,9 the precise role of cCTA (versus stress testing or in
combination with stress testing) in the work-up of CAD remains poorly defined.
In this study, we apply a theoretical decision analytic model to evaluate the diagnostic
accuracy, effective radiation dose and imaging costs associated with evaluation of CAD using
various combinations of cCTA and stress testing. Our goal is to define the strengths and
weaknesses of various testing strategies that may be employed in order to optimize evaluation of
the symptomatic patient with suspected obstructive CAD.

Methods:

A decision tree was constructed to compare false negative rates, false
positive rates, effective radiation exposure and imaging costs during the work-up of
suspected coronary disease with stress testing and/or cCTA (figure 1). The decision
tree begins with a decision node – the rectangular box – where a CAD work-up
strategy is chosen. The work-up options include evaluation with a single stress test
or by cCTA alone, as well as options for a combined evaluation with both stress
testing and cCTA. Each individual test option is represented by a node – a circle –
whose outcome is governed by the sensitivity and specificity of that particular test.
The work-up strategy follows the upper branch out of the test node when the test is
positive, and the lower branch out of the test node when the test is negative. For
combined evaluations, the decision tree includes options that begin with a stress test
and proceed to cCTA as well as options that begin with cCTA and proceed to a
stress test. In order to minimize unnecessary cardiac catheterizations, patients in
this model are referred to catheterization only when non-invasive diagnostic testing
is positive. When an option for combined testing is chosen, the patient is referred
for the second test only if the first test is positive, and is referred to catheterization
only when both the stress test and the cCTA are positive.
Spreadsheet computations for expected rates (or proportions) of true and
false diagnoses among the population presenting for diagnostic testing were
implemented as follows:
True positive rate (TPR) = prevalence x sensitivity
False negative rate (FNR) = prevalence - True positive rate
True negative rate (TNR) = (1 – prevalence) * specificity
False positive rate (FPR) = (1- prevalence) – True negative rate

It is important to distinguish the positive and negative rates/proportions in a study
population (as defined above) from the positive and negative rates of a diagnostic
examination. With respect to a diagnostic examination, the TPR (sensitivity), FNR
(1-sensitivity), TNR (specificity) and FPR (1-specificity) are defined independent of
disease prevalence. However, the expected proportion of positive and negative tests
in a population and are dependent upon disease prevalence. For the purpose of
health care policy decisions, the proportion of correct diagnoses in a study
population (TPR + TNR), the proportion of incorrect diagnoses in a study
population (FPR + FNR) and the overall imaging costs in the population are of
interest. The TPR, TNR, FPR, and FNR of individual diagnostic tests are only
important in so far as they impact the proportion of correct and incorrect diagnoses
in the population. For the remainder of this manuscript all references to positive
and negative rates refer to proportions within the study population.

Although CAD may be defined by gradations of severity, we use a
dichotomous definition for CAD to simplify the decision analysis. cCTA is defined
as positive for the presence of atherosclerotic disease when there is more than 50%
diameter narrowing. The results of cardiac catheterization (our “gold standard”) are
assumed to be correct. Expected rates of true and false diagnoses are propagated
through the decision tree based upon a Bayesian analysis that depends only upon
prevalence of disease in the study population (= pre-test probability of disease for
the individual patient) and the sensitivity/specificity of each test. At each testdecision node within the tree, the expected rate of positive exams is calculated as the
sum of the true positive rate + false positive rate while the expected rate of negative
exams is calculated as the sum of the true negative rate + false negative rate.

For any particular work-up strategy in the decision tree, effective radiation
dose is computed as the sum of the effective radiation dose for each test in the
pathway multiplied by the proportion of patients who will be subjected to that test.
Imaging cost is similarly computed as the sum of the imaging cost for each test in
the pathway multiplied by the proportion of patients who will be subjected to that
test. Since the cost of cardiac catheterization is far greater than the cost of stress
testing and cCTA, a strategy that employs more testing can result in reduced
imaging costs if the rate of cardiac catheterizations is reduced.

A range of values for the sensitivity and specificity of stress tests and cCTA
are reported in the literature. The values used for this analysis are summarized in
table 1. The values for stress testing are based upon published meta analyses of the
literature for stress ECG testing10 as well as stress echocardiography and stress
MPS.11 The sensitivity and specificity of cCTA for CAD with diameter stenosis
greater than 50% were based upon a recent multicenter trial by Budoff.12 A
sensitivity analysis was performed by varying the sensitivity and specificity of
cCTA according to values obtained in two other recent multicenter trials – one trial
by Meijboom demonstrating lower specificity,13 and a second trial by Miller
demonstrating lower sensitivity.14 Our primary analysis was based upon
sensitivity/specificity data from the Budoff trial because these values are
intermediate between those of Meijboom and Miller. Finally, although single center
trials may overestimate the accuracy of a diagnostic study, several recent meta
analyses of single center studies have suggested higher diagnostic accuracy than the
multicenter trials referenced above.3,4 Therefore, higher values of sensitivity and
specificity were also tested based upon the analysis of Vanhoenacker.3

Effective radiation dose for stress MPS, cCTA and diagnostic cardiac
catheterization is a moving target with improvements in technology. Effective
doses used for the current analysis are summarized in table 2. For stress MPS, the
base value used for the analysis was 12mSv, based upon the reported dose for a Tc99m sestamibi 1-day rest-stress protocol.15 For the purpose of sensitivity analysis,
the dose of a stress MPS examination was also varied down to 9.4mSv as reported
in a more recent review of nuclear medicine studies.16 In the interest of using an
effective dose that is obtained with the latest generally available technology, we
assume a 4.2mSv effective dose for prospectively ECG-gated cCTA based upon
clinical reports.17,18 For the purpose of sensitivity analysis, since many centers have
not yet adopted prospectively gated cCTA, the effective dose of cCTA was also
varied up to 10mSv as demonstrated in a recent multicenter trial using the more
conventional helical CTA with tube current modulation.19 The effective dose for
diagnostic cardiac catheterization was set at 7mSv for the base analysis, but was
,

varied down to 5mSv for the sensitivity analysis.20 21

Imaging/testing costs were computed as a combination of professional and
technical fees as reported in table 3. For the purpose of cost comparisons, we refer
to these costs as imaging costs even though the stress ECG study does not include
an imaging component. Professional and technical fees for stress testing, cCTA and
diagnostic cardiac catheterization were obtained from the 2009 physician Medicare
fee schedule provided by our local carrier (Highmark Medicare; Camp Hill, PA).
These fees are very similar to the 2009 national average Medicare payments (based
upon the Nov 2008 Federal Register using a 2009 conversion factor –
http://www.bostonscientific.com/Reimbursement). The facility fee for cardiac
catheterization was not available in the 2009 physician medicare fee schedule

provided by our local carrier, and was therefore based upon the national average
facility fee from the Federal Register.

The decision tree model was implemented on a spreadsheet (Quattro Pro;
Correl Corp. Ottawa, Ontario). Computed values of false negative rates, false
positive rates, costs and radiation exposure were obtained for a disease prevalence
(= pre-test probability) that ranged from 0.01 to 0.60. The calculated values
represent expected mean values as a function of CAD prevalence. Results of this
analysis are presented in graphical format.

Results:

The imaging cost and expected effective radiation dose associated with each
of the various work-up strategies for CAD are depicted to the right side of each
terminal branch of the decision tree in figure 1. Figures 2 and 3 demonstrate the
false negative and false positive rates for the diagnosis of CAD as a function of
CAD prevalence, using our baseline assumptions of sensitivity and specificity
(Budoff). Table 4 reports the values of these positive and negative work-up rates as
a function of the prevalence of CAD. The order in which the stress test and cCTA
are performed make no difference in this calculation. False negative rate (FNR) is
proportional to CAD prevalence while false positive rate (FPR) is inversely related
to CAD prevalence. FNR is lowest when cCTA is used as an isolated test. When a
stress test is used in combination with cCTA, the FNR is slightly higher compared
with the FNR when the same stress test is used alone. Specifically, the FNR of a
combined approach including cCTA is increased by up to 3% relative to the FNR of
a stress test alone as the prevalence of CAD approaches 60%. However, the FPR of
the combined approach is reduced by 9-19% as the prevalence of CAD approaches
1%. FPR is minimized when cCTA is employed in combination with stress
echocardiography.

Figure 4 demonstrates expected effective radiation dose as a function of
CAD prevalence. Strategies that employ no advanced imaging (0.0mSv) or proceed
directly to cardiac catheterization (7.0mSv) are not demonstrated in this figure since
the effective radiation dose for these strategies is independent of CAD prevalence.
Strategies that use stress MPS result in a higher effective dose than all other
strategies. Stress MPS alone results in an effective dose that is approximately 8mSv

higher than cCTA alone. When a stress ECG or stress echocardiogram is added
following cCTA, effective radiation dose is reduced by approximately 1mSv
relative to cCTA alone. However, when a stress ECG or stress echocardiogram is
added prior to cCTA, effective radiation dose is reduced by 4-5mSv because fewer
cCTA studies are performed. A work-up strategy that employs stress ECG or stress
echocardiography prior to cCTA minimizes effective radiation exposure compared
to all other strategies that use cCTA and/or MPS. When the prevalence of CAD is
below 47%, a strategy that employs stress echocardiography followed by cCTA will
result in an expected effective radiation dose that is below that of a single cCTA
(4.2mSv). When the prevalence of CAD is below 10%, a strategy that employs
stress echocardiography followed by cCTA may actually result in an effective
radiation dose that is lower than a strategy that uses stress echocardiography alone.

Overall imaging costs are summarized in figure 5 as a function of CAD
prevalence. A strategy that tests all patients with cardiac catheterization is not
demonstrated in figure 5 as this strategy would result in a fixed imaging cost of
$2948, independent of CAD prevalence. As long as the pre-test probability of CAD
is below 75%, the cost for each of the remaining strategies is below the cost of
proceeding directly to cardiac catheterization. When the prevalence of CAD is
below 45%, a strategy that employs stress MPS together with cCTA will result in
lower rates of cardiac catheterization and lower imaging costs as compared to a
strategy that uses either MPS or cCTA alone. Imaging costs are minimized by a
strategy that employs stress ECG followed by cCTA. This combined strategy saves
at least $400 per patient relative to a strategy that combines stress MPS with cCTA.
From the imaging cost perspective, a strategy that employs stress echocardiography
followed by cCTA is the second best strategy provided the prevalence of CAD is

below 20%. As demonstrated in figures 2 and 3, the diagnostic accuracy (FPR and
FNR) of a strategy that employs stress echocardiography followed by cCTA is
superior to that of stress ECG followed by cCTA.

Figure 6 demonstrates a sensitivity analysis for effective radiation dose.
Figure 6A demonstrates effective radiation based upon a lower assumption of dose
for stress MPS (9.4mSv) and cardiac catheterization (5mSv), while figure 6B
demonstrates effective radiation based upon a higher assumption of dose for cCTA
(10.0mSv). Figure 6C demonstrates the effective radiation dose based upon a
combination of the lower dose assumptions for stress MPS and cardiac
catheterization with the higher assumption for cCTA. Although the overall effective
radiation doses are different from those demonstrated in figure 4, there is a similar
pattern in the relative ordering of work-up strategies with respect to effective dose.
Strategies that employ stress ECG or stress echocardiography alone or followed by
cCTA continue to result in the lowest effective radiation dose. Similar graphs of
effective radiation dose were produced when the diagnostic accuracy of cCTA was
based upon the data of Miejboom (figure 6D) or Miller (figure 6E).

Figure 7 demonstrates a sensitivity analysis for expected imaging costs
based upon various diagnostic accuracies of cCTA. The Miejboom values (figure
7A - lower specificity of cCTA) result in a higher FPR for cCTA, more cardiac
catheterization procedures and higher overall imaging costs associated with options
that include cCTA evaluation. The Miller values (figure 7B - lower sensitivity of
cCTA with higher specificity) result in a lower FPR for cCTA and are associated
with lower overall imaging costs. Notwithstanding the differences in absolute
imaging costs, analyses based upon both the Miejboom and Miller data both

demonstrate that imaging costs are minimized by a strategy that employs stress ECG
followed by cCTA. A strategy that employs stress echocardiography followed by
cCTA is the second best strategy from a cost prospective in the setting of low CAD
prevalence. When the sensitivity and specificity of cCTA are set to higher values
based upon the meta analysis of Vanhoenacker (figure 7C) overall imaging costs
with a cCTA work-up are reduced in comparison to the baseline analysis (figure 5).

Discussion:

We have applied a decision theoretic model to define the optimal roles of
stress testing and cCTA in the work-up of the symptomatic patient with CAD. Our
model demonstrates that when a stress ECG or stress echocardiogram is added prior
to cCTA, the number of unnecessary cardiac catheterizations, the effective radiation
dose and the imaging costs of the work-up may be minimized. The combination of
stress echocardiography followed by cCTA results in a FNR that is slightly higher
than stress MPS alone (up to 8% higher at a CAD prevalence of 50%), but it
minimizes the FPR of CAD diagnosis (by approximately 20% relative to MPS alone
at a CAD prevalence of 10%). Previous studies have noted that stress testing and
cCTA provide complementary functional and anatomic information.7 Our study
demonstrates that a combination of stress testing and cCTA may be complementary
from the viewpoint of minimizing effective radiation dose and imaging costs.

The clinical application of our results is best illustrated by an example.
Assume that we have a symptomatic patient with a 10% pre-test probability of
clinically significant CAD (a reasonable assumption for many patients who present
to the emergency department with chest pain). The least expensive options for
evaluation as demonstrated in figure 5 begin with a stress ECG followed by cCTA
at an expected imaging cost of $591 or with stress echocardiography followed by
cCTA at an expected cost of $807. If the evaluation is performed only with cCTA
the expected cost rises to $1412. If the evaluation is performed only with a nuclear
stress MPS test the expected cost rises to $1532. The estimated FNR for these
approaches is 3.6% for stress ECG + cCTA, 2.8% for stress echocardiography +

cCTA, 1.2% for stress MPS alone and 0.6% for cCTA alone (figure 2). The FPR (=
the rate of unnecessary cardiac catheterizations) is 3.5% for stress ECG + cCTA,
1.8% for stress echocardiography + cCTA, 21% for stress MPS alone and 15% for
cCTA alone (figure 3). Expected effective radiation dose would be minimized to
1.4mSv by evaluation with stress echocardiography + cCTA while dose is
maximized to 14.1mSv by evaluation with stress MPS alone (figure 4). The lower
radiation dose and costs associated with stress ECG + cCTA or stress
echocardiography + cCTA are related to the decreased FPR and greatly reduced
number of unnecessary cardiac catheterizations. These cost savings and the lower
morbidity related to fewer cardiac catheterizations must be weighed against a 1.6%
increase in the FNR of the work-up with stress echocardiography + cCTA relative to
stress MPS alone.

The most appropriate testing strategy for the work-up of symptomatic CAD
depends upon the pre-test probability of disease which can be estimated on the basis
of clinical presentation.22 When the pre-test probability of disease is very high the
patient should be triaged directly to cardiac catheterization. For the patient
described above with a low pre-test probability of disease (≤ 20%), the
combinations of stress ECG + cCTA or stress echocardiography + cCTA provide
optimal options as judged by cost and radiation dose, while stress echocardiography
+ cCTA is optimal as judged by FPR. As the pre-test probability of CAD increases,
FNR becomes a greater consideration. For a symptomatic patient with a pre-test
probability of disease approaching 60%, the least expensive option for evaluation is
stress ECG at $1,584, but stress ECG is associated with a FNR of 19% and is
probably not appropriate. Stress ECG + cCTA has an estimated cost of $1,639 and
is associated with a FNR of 22%, while stress echocardiography + cCTA has an

estimated cost of $2,059 and is associated with a FNR of 17%. Evaluation with
stress MPS alone has an estimated cost of $2,490, a radiation dose of 16.3mSv and a
FNR of 7.2%. Evaluation with cCTA alone has an estimated cost of $2,562, a
radiation dose of 8.7mSv and a FNR of 3.6%. Our analysis demonstrates that
evaluation by cCTA alone is superior to all other non-invasive testing options in
terms of FNR, and thus may be a more appropriate option for the patient with an
intermediate pre-test probability of disease (> 20%).

In our clinical experience the MPS study is the most common form of stress
test requested for evaluation of suspected CAD. Stress MPS is often advocated as
superior to stress echocardiography because it is less operator dependent. Large
studies suggest that the overall diagnostic performance of stress echocardiography is
equivalent to that of stress MPS in the diagnosis of CAD.23 Furthermore, as
demonstrated in our analysis, use of stress echocardiography reduces the false
positive rate, effective radiation dose and imaging costs relative to stress MPS. Our
decision analysis suggests that a combination of stress ECG with cCTA or stress
echocardiography with cCTA provides an optimal work-up for symptomatic CAD
in a low prevalence population, while cCTA alone may be more appropriate in an
intermediate prevalence population. For the low prevalence population, if one
wishes to minimize radiation dose, the stress test should be performed prior to
cCTA. If the referring physician wishes to know about the anatomic presence of
CAD – irrespective of whether the disease is hemodynamically significant - it may
be reasonable to begin the work-up with cCTA and progress to a stress test based
upon a positive cCTA.

A decision analysis model is only as good as the probability values that are

used to define the test nodes. We have chosen generally accepted values based upon
large meta analysis studies for the sensitivity and specificity of stress testing.10,11
With respect to cCTA, there is much controversy in the published literature about
the true diagnostic accuracy of the technique. Furthermore, given the rapid pace of
technological progress in cCTA, these numbers are constantly improving. Because
the reported sensitivity and specificity with this relatively new technology varies
among different centers, we chose to base our analysis on recently published
multicenter trials of cCTA with cardiac catheterization as the gold standard.
Unfortunately, these multicenter trials also differ in the reported values of
sensitivity/specificity for cCTA. We chose to use the sensitivity/specificity values
reported by Budoff for our primary calculations,12 but performed a sensitivity
analysis with the values reported by Meijboom demonstrating higher sensitivity
with lower specificity,13 as well as the values reported by Miller demonstrating
lower sensitivity with higher specificity.14 Finally, because cCTA is a rapidly
improving technology, we performed an additional analysis based upon the higher
values of sensitivity/specificity reported in recent meta analyses of single center
studies.3,4

When interpreting a stress test or cCTA, results are often presented on a
spectrum that extends from a truly negative test to a grossly positive test. Clearly, a
stress MPS study that demonstrates an ECG abnormality along with a large
reversible perfusion defect is more definitive than a study that demonstrates only a
small fixed perfusion deficit. Likewise a cCTA that suggests a 90% stenosis of the
proximal left anterior descending artery may be more definitive than a study that
suggests a 50% lesion in the sub-optimally visualized mid-portion of the right
coronary artery. In some patients, diagnostic testing with a stress test or cCTA may

provide an indeterminate result. Nonetheless, since sensitivity/specificity values for
stress testing and cCTA are available only for dichotomous test results, our decision
analysis assumes a dichotomous test result (normal versus abnormal study) for
stress testing, cCTA and cardiac catheterization.

Much of the cost savings of noninvasive testing results from avoiding cardiac
catheterization in patients without true CAD. In addition to the benefits of reduced
radiation exposure and costs, fewer cardiac catheterizations will result in reduced
complications from interventional angiography. In the clinical setting, however, a
mildly abnormal stress test or cCTA that does not indicate multivessel disease may
not proceed to cardiac catheterization. Results of the COURAGE trial suggest that
non-invasive medical therapy may be an equally appropriate option for these patients
when judged in terms of mortality and future coronary events.24 Nonetheless, among
the subgroup of COURAGE patients evaluated with stress MPS, patients who
proceeded to cardiac catheterization and angioplasty demonstrated a reduced
ischemic burden.25 Furthermore, a subsequent quality of life analysis among
COURAGE participants demonstrated a small, but significant early improvement in
quality of life among symptomatic patients who proceeded to cardiac catheterization
and angioplasty.26 Although mildly abnormal test results may not proceed to further
testing in all patients, our analysis required a standard dichotomous decision model to
compute diagnostic accuracy, expected radiation exposure and costs. Based upon the
results reported in the subgroup of COURAGE patients evaluated with stress MPS,
we assume that a positive stress test in a symptomatic patient should trigger the
performance of another test, potentially culminating in cardiac catheterization so that
the patient may be treated with a stent or surgery for symptomatic relief.

With respect to cCTA, we chose to apply a cutoff of 50% diameter stenosis
as the distinction between normal and abnormal. In the cardiac catheterization
laboratory, a cutoff value of 70% is more commonly used to trigger a decision for
angioplasty or surgery. In many cases, the decision for intervention is based on
measurement of a pressure gradient that cannot be directly predicted from the
degree of anatomic stenosis. For the purpose of the current analysis, however, we
are limited by the fact that most studies document the sensitivity and specificity of
cCTA to predict a 50% diameter stenosis. Little data is available on the accuracy of
cCTA for other levels of arterial stenosis. Of note, the Budoff study that we used to
provide our baseline values for sensitivity and specificity reports the diagnostic
accuracy of cCTA for both 50% and 70% diameter reduction. The sensitivity of
cCTA to detect a stenosis with ≥ 50% diameter reduction is 95% while the
sensitivity of cCTA to detect a stenosis with ≥ 70% diameter reduction is 94%. The
specificity was constant at 83% for both levels of stenosis.12 Based upon our
sensitivity analysis, it is clear that this difference of 1% in sensitivity would make
little difference in our overall analysis.

Although our decision tree considers the imaging costs included in the noninvasive (stress test, cCTA) and invasive (cardiac catheterization) work-up of
suspected CAD, the analysis does not include future outcomes associated with
correct and incorrect diagnoses of CAD. The various work-up options on the tree
will result in different frequencies of cardiac catheterization and therefore in
different treatment decisions for a small minority of patients. Although we present
the FPR and FNR associated with each testing strategy, we do not attempt to define
the cost of false positive and false negative test results. Ignoring these future costs is

a major limitation of this study. However, although the cost of ultimate outcomes is
important, this cost is very difficult to define. There is no published data to define
the benefit of coronary intervention with angioplasty or surgery in patients with
stenosis identified by cardiac catheterization but who have a negative stress test
and/or negative cCTA. As suggested by the COURAGE trial, there is probably little
mortality benefit from invasive therapy for single vessel CAD, though there may be
some benefit in terms of ischemic burden and quality of life.25,26 We believe that
there is insufficient data to allow an accurate cost-effectiveness analysis of stress
testing versus cCTA based upon long term outcomes. We have therefore decided to
limit our analysis to the radiation dose and costs associated with the non-invasive
and invasive diagnostic imaging components of the work-up for CAD.

In conclusion, when considering the work-up of CAD in the symptomatic
patient, the FNR of cCTA is below that of stress testing at all levels of CAD
prevalence. The combination of cCTA with any stress study results in a decreased
FPR relative to a stress study alone. The FPR of a CAD evaluation is minimized
when cCTA is employed in combination with stress echocardiography. Radiation
dose is minimized by starting the work-up with stress ECG or stress
echocardiography prior to cCTA. Finally, when the clinical scenario warrants
further diagnostic testing for CAD, a work-up strategy that employs stress
echocardiography followed by cCTA is an excellent approach to evaluate the low
risk CAD patient, while cCTA alone may be more appropriate in the intermediate
risk patient.

Figure Captions:

Figure 1. Decision tree for the work-up of symptomatic CAD. The decision tree
begins on the left side with a decision node – the rectangular box – where a CAD
work-up strategy is chosen. The option at the very top of the tree corresponds to no
advanced testing such that all patients are treated medically. The option at the
bottom of the tree corresponds to cardiac catheterization for all patients. The
remaining work-up options include evaluation with a stress test and/or cCTA. Each
non-invasive test is identified by a round “chance” node which uses the sensitivity
and specificity associated with the test to propagate positive and negative detection
rates down the tree. At the terminal points of the tree (marked by arrows) the
effective radiation dose and imaging cost for each pathway is computed. The focus
of this study is to distinguish the strengths and weaknesses of these various work-up
options.

Figure 2. False negative work-up rates for the diagnosis of CAD using baseline
assumptions of sensitivity and specificity from the study of Budoff.

Figure 3. False positive work-up rates rates for the diagnosis of CAD using baseline
assumptions of sensitivity and specificity from the study of Budoff.

Figure 4. Effective radiation dose for the evaluation of suspected CAD using
baseline assumptions of sensitivity and specificity from the study of Budoff and
effective radiation doses of 4.2mSv for cCTA, 12mSv for stress MPS and 7mSv for
cardiac catheterization.

Figure 5. Imaging costs for the evaluation of suspected CAD using baseline
assumptions of sensitivity and specificity from the study of Budoff.

Figure 6. Sensitivity analysis for effective radiation dose in the evaluation of CAD.
(A) Presents expected dose using lower estimates for effective radiation for stress
MPS (9.4mSv) and cardiac catheterization (5mSv).
(B) Presents expected dose using a higher estimate for effective radiation of cCTA
(10.0mSv).
(C) Presents expected dose using lower estimates for effective radiation for stress
MPS (9.4mSv) and cardiac catheterization (5mSv) in combination with a higher
estimate for effective radiation of cCTA (10.0mSv).
(D) Presents expected dose based upon the data of Miejboom and our baseline
assumptions of effective radiation doses of 4.2mSv for cCTA, 12mSv for stress
MPS and 7mSv for cardiac catheterization.
(E) Presents expected dose based upon the data of Miller and our baseline
assumptions of effective radiation doses of 4.2mSv for cCTA, 12mSv for stress
MPS and 7mSv for cardiac catheterization.

Figure 7. Sensitivity analysis for expected imaging costs in the evaluation of CAD.
(A) Presents expected imaging costs based upon the sensitivity and specificity data
of Miejboom.
(B) Presents expected imaging costs based upon the sensitivity and specificity data
of Miller.
(C) Presents expected imaging costs based upon higher values of sensitivity and
specificity in the meta analysis of Vanhoenacker.
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